1. Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohort.
- Author
-
Metges JP, Genet D, Tougeron D, Ligeza C, Ducreux M, Borg C, Guimbaud R, Phelip JM, Dourthe LM, and Kim S
- Subjects
- Adult, Aged, Aged, 80 and over, Asthenia chemically induced, Asthenia etiology, Colorectal Neoplasms mortality, Colorectal Neoplasms pathology, Disease-Free Survival, Female, France epidemiology, Hand-Foot Syndrome etiology, Humans, Hypertension chemically induced, Male, Middle Aged, Phenylurea Compounds administration & dosage, Progression-Free Survival, Prospective Studies, Pyridines administration & dosage, Asthenia epidemiology, Colorectal Neoplasms drug therapy, Hand-Foot Syndrome epidemiology, Hypertension epidemiology, Phenylurea Compounds adverse effects, Pyridines adverse effects
- Abstract
Aim: We report real-world evidence with regorafenib in previously treated metastatic colorectal cancer from the French cohort of the international, prospective, observational CORRELATE study. Patients & methods: Patients receiving regorafenib according to French health authority approval were included. The primary end point was treatment-emergent adverse events. Overall survival and progression-free survival were secondary end points. Results: Two hundred and forty-two patients (61% male, median age: 66 years) were enrolled. The most common grade ≥3 drug-related treatment-emergent adverse events were hand-foot skin reaction (10.3%), asthenia/fatigue (9.9/1.2%) and hypertension (6.2%). Median overall survival and progression-free survival were 6.8 (95% CI: 6.3-7.6) and 2.8 months (95% CI: 2.6-3.0), respectively. Conclusion: The real-world safety and effectiveness data of regorafenib in metastatic colorectal cancer in France align with findings from Phase III clinical trials and the global CORRELATE population.
- Published
- 2021
- Full Text
- View/download PDF